drugset / Trial / NCT06056921
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm study to evaluate the efficacy and safety of CD19 targeted CAR-T cells therapy for patients with Refractory Autoimmune Disease
Timeline
- Start
- 2023-08-31
- Primary completion
- 2025-12-31
- Completion
- 2026-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19-targeted CAR-T cells | Cell therapy | — | Intravenous |